Unknown

Dataset Information

0

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden.

ABSTRACT:

SUBMITTER: McKay KA 

PROVIDER: S-EPMC8637249 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden.

McKay Kyla A KA   Piehl Fredrik F   Englund Simon S   He Anna A   Langer-Gould Annette A   Hillert Jan J   Frisell Thomas T  

JAMA network open 20211201 12

Similar Datasets

Unknown Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
| S-EPMC9857265 | biostudies-literature
Unknown Rituximab for people with multiple sclerosis.
| S-EPMC8574640 | biostudies-literature
Unknown Multiple sclerosis, rituximab, and COVID-19.
| S-EPMC8045943 | biostudies-literature
Unknown Rituximab treatment in pediatric-onset multiple sclerosis.
| S-EPMC11235651 | biostudies-literature
Unknown Association between informal help and background factors for persons with multiple sclerosis in Sweden: a cross-sectional study.
| S-EPMC12434731 | biostudies-literature
Unknown Serum sickness following rituximab therapy in multiple sclerosis.
| S-EPMC6927430 | biostudies-literature
Unknown Formal help for persons with multiple sclerosis-Background factors associated with usage of personal assistance and home help in Sweden.
| S-EPMC10194947 | biostudies-literature
Unknown Rituximab for the treatment of multiple sclerosis: a review.
| S-EPMC7790722 | biostudies-literature
Unknown Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients.
| S-EPMC9696175 | biostudies-literature
Unknown Dose-finding designs for cumulative toxicities using multiple constraints.
| S-EPMC6296314 | biostudies-literature